Top Tech Companies (29)
SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others. With antibiotic resistance increasing in the world, SaNOtize's platform technology can help fight resistance and bring a new innovating solution to fight infections.
Lucent Bio is on a mission to accelerate the transition to a sustainable agri-food system through innovative crop input solutions that are climate-positive, non-polluting, and based on circular economy principles. Our products; Soileos, a micronutrient fertilizer, Nutreos, a microplastic-free seed coating; and Agreos, a microplastic-free controlled release fertilizer coating, harness the power of nature to deliver climate-positive results to Agri-food systems.
Virogin Biotech aims to be a global, best-in-class oncolytic virus company that creates impactful drugs for patients of the highest medical need. Our platform technology focuses on creating long-lasting antitumor immunity by capitalizing on a robust, transient antiviral immune response through a synergy with multiple payload expression. Virogin is designing a more potent oncolytic virus, expressing optimized payloads to enhance the systemic antitumor immunity in relapsed/refractory cancers. Led by our leadership team with over 25 years of experience in fundamental research, translational and clinical development of immunotherapy & oncolytic virotherapy, we are determined to bring our novel therapies for relapsed/refractory cancers to market.
Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers to better prioritize patients by medical urgency, spend less on management and logistics and ultimately save more lives.
Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To provide our partners with the best LNP delivery technology for nucleic acid therapeutics · To support our partners to rapidly advance new therapeutics to address unmet medical needs · To continually innovate to maintain and strengthen our LNP technological lead Acuitas partners locally and globally with companies, academic institutes and other organizations to improve human health.
Brains Bioceutical Corp is a globally recognized leader in GMP-certified production of naturally-sourced Active Pharmaceutical Ingredients (API). #MadeBetter
Vesalius Cardiovascular is a Canadian medical device company founded in 2016 in Vancouver, Canada. The company specializes in designing and developing biomedical devices for the treatment of cardiovascular disease, specifically mitral valve regurgitation (MR). We are preclinical. Our devices will be introduced percutaneously (transfemoral/transseptal) to the heart, eliminating the need for open heart surgery and the related risks. The procedure can be performed by a Cardiovascular Interventionalist (Cardiologist or Cardiac Surgeon). Vesalius Cardiovascular is the result of several years of intensive private research and investigation. The inventor behind Vesalius Cardiovascular is Dr. Peter Skarsgard, a Vancouver-based Cardiac Surgeon, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital. Our Advisory Board includes some of BC’s most prominent clinicians, including: - Peter Skarsgard (MD), Cardiac Surgeon and Head of Cardiovascular Surgery at VGH - Christopher Durkin (MD), Anaesthesiologist with advanced expertise in 3D echo for intracardiac structural disease - Jacqueline Saw (MD), Interventional Cardiologist with specialized expertise in percutaneous device delivery and structural heart intervention Vesalius Cardiovascular is currently developing Calla, a biomedical device that can be introduced percutaneously (transfemoral/transseptal) to the heart, for the treatment of degenerative MR (due to mitral valve prolapse), the most common variety of MR. The principles of surgical mitral valve repair are utilized, but sternotomy, heart-lung bypass, and cardiac arrest - components of an open heart operation - are not required
Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers to better prioritize patients by medical urgency, spend less on management and logistics and ultimately save more lives.
Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy
